Separate terms with OR to return results that match either term.
 
Clear All

716 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class (Ascending) Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9076 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 July 23, 2021 Sept. 27, 2021 No Longer Used
C9081 Idecabtagene vicleucel Abecma up to 460000000 Immunotherapy CAR-T BCMA No 2021 Sept. 27, 2021 Jan. 26, 2022 No Longer Used
Q2054 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Sept. 27, 2021 In Use
Q2055 Idecabtagene vicleucel Abecma 460 million Immunotherapy CAR-T BCMA No 2021 Jan. 26, 2022 In Use
Q2056 Ciltacabtagene autoleucel CARVYKTI up to 100 million Immunotherapy CAR-T No 2022 Sept. 27, 2022 In Use
C9098 Ciltacabtagene autoleucel CARVYKTI up to 100 million Immunotherapy CAR-T No 2022 March 25, 2022 Sept. 27, 2022 No Longer Used
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct. 1, 2017 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct. 1, 2016 In Use
C9492 Durvalumab Imfinzi 10 mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Oct. 1, 2017 In Use
J9228 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jan. 1, 2012 In Use

Found 716 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.